Journal
INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 16, Issue -, Pages 297-314Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S284357
Keywords
phenylboronic acid; glucose sensitive; diabetes
Funding
- Key Laboratory of Microcosmic Syndrome Differentiation, Education Department of Yunnan Project [20190720]
- Yunnan Province Applied Basic Research Project [2019FF002 (-055)]
Ask authors/readers for more resources
Glucose-sensitive self-adjusting drug delivery system mimics the physiological model of insulin secretion from the human pancreas, controlling blood sugar by precisely regulating the release of hypoglycemic drugs, showing promising application prospects in diabetes treatment.
The glucose-sensitive self-adjusting drug delivery system simulates the physiological model of the human pancreas-secreting insulin and then precisely regulates the release of hypoglycemic drugs and controls the blood sugar. Thus, it has good application prospects in the treatment of diabetes. Presently, there are three glucose-sensitive drug systems: phenylboronic acid (PBA) and its derivatives, concanavalin A (Con A), and glucose oxidase (GOD). Among these, the glucose-sensitive polymer carrier based on PBA has the advantages of better stability, long-term storage, and reversible glucose response, and the loading of insulin in it can achieve the controlled release of drugs in the human environment. Therefore, it has become a research hotspot in recent years and has been developed very rapidly. In order to further carry out a follow-up study, we focused on the development process, performance, and application of PBA and its derivatives-based glucose-sensitive polymer drug carriers, and the prospects for the development of this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available